2-Aminopurine

2-Aminopurine

SCHEMBL5529464

Nc1ncc2nc[nH]c2n1.OC[C@H]1OC(O)[C@H](O)[C@@H]1O

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
ALDH1A1 P00352 2/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
NFKB1 P19838 1/20 0.41
DNMT1 P26358 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
BLM P54132 1/20 0.41
HBB P68871 1/20 0.41
PMP22 Q01453 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
PNP P00491 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
ADORA1 P30542 1/20 0.35
HIF1A Q16665 2/20 0.35
NT5E P21589 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ribose (Furanose) SCHEMBL4391869 0.82 ADA (0.47) LMNAALDH1A1SMN1; SMN2POLBPNP
2,6-Diaminopurine SCHEMBL8153506 0.80 HIF1A (0.42) LMNAALDH1A1GMNNTP53NFKB1
2,6-Diaminopurine SCHEMBL10774599 0.80 HIF1A (0.42) LMNAALDH1A1GMNNTP53NFKB1
2-Aminopurine SCHEMBL28775710 0.80 ALDH1A1 (0.59) LMNAALDH1A1GMNNTP53NFKB1
SCHEMBL3664019 0.78 PYGL (0.41) LMNAGMNNNFKB1BLMPMP22
SCHEMBL2914676 0.78 PYGL (0.41) LMNAGMNNNFKB1BLMPMP22
SCHEMBL10666441 0.78 PYGL (0.41) LMNAGMNNNFKB1BLMPMP22
SCHEMBL6935271 0.78 PYGL (0.41) LMNAGMNNNFKB1BLMPMP22
SCHEMBL17364274 0.78 PYGL (0.41) LMNAGMNNNFKB1BLMPMP22
SCHEMBL3727543 0.78 PYGL (0.41) LMNAGMNNNFKB1BLMPMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7297787-B2 Process for preparing N6 substituted aminopurine ribofuranose nucleosides GLAXO GROUP LIMITED (GB) 2007-11-20 US disclosed
US-7297787-B2 Process for preparing N6 substituted aminopurine ribofuranose nucleosides GLAXO GROUP LIMITED (GB) 2007-11-20 US disclosed
EP-1370569-B1 PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES GLAXO GROUP LTD (GB) 2005-08-31 EP disclosed
US-20050176949-A1 Process for preparing N6 substituted aminopurine ribofuranose nucleosides GLAXO GROUP LIMITED (GB) 2005-08-11 US disclosed
US-20050176949-A1 Process for preparing N6 substituted aminopurine ribofuranose nucleosides GLAXO GROUP LIMITED (GB) 2005-08-11 US disclosed
EP-1370569-A1 PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES GLAXO GROUP LIMITED (GB) 2003-12-17 EP disclosed
EP-1370569-A1 PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES GLAXO GROUP LIMITED (GB) 2003-12-17 EP disclosed
WO-2002074781-A1 PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES GLAXO GROUP LIMITED (GB) 2002-09-26 WO disclosed
WO-2002074781-A1 PROCESS FOR PREPARING N6-SUBSTITUTED AMINOPURINE RIBOFURANOSE NUCLEOSIDES GLAXO GROUP LIMITED (GB) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050176949-A1 Process for preparing N6 substituted aminopurine ribofuranose nucleosides ADORA3, NUDT1, ADORA1 LMNA 1864/4885ALDH1A1 1388/4885GMNN 550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.